Cytokinetics' Myqorzo Could Inflect Revenue Starting 2027, RBC Capital Markets Says
Leerink Partners Maintains Outperform on Cytokinetics, Lowers Price Target to $100
Cytokinetics (CYTK) Could Be 41% Undervalued Following Strong Q3 And Aficamten Data
Loading...